Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study
作者： M. Bruzzone , M.G. Centurioni , P. Giglione , M. Gualco , D.F. Merlo
DOI: 10.1159/000328451
关键词:
摘要: Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction platinum. One major reasons for this failure is lack o
core.ac.uk
elsevier.com
karger.com
sci-hub.se 参考文章(37)
Larry W. Hertel, Peng Huang, William Plunkett, Gerald B. Grindey, Sherri Chubb, Sherri Chubb, Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Research. ,vol. 51, pp. 6110- 6117 ,(1991)
P G Rose, J A Blessing, A R Mayer, H D Homesley, Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology. ,vol. 16, pp. 405- 410 ,(1998) , 10.1200/JCO.1998.16.2.405
M. A. Bookman, GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma Journal of Clinical Oncology. ,vol. 24, pp. 5002- 5002 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.5002
R. de Wit, M.E.L. van der Burg, A.v.d. Gaast, A. Logmans, G. Stoter, J. Verweij, Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Annals of Oncology. ,vol. 5, pp. 656- 657 ,(1994) , 10.1093/OXFORDJOURNALS.ANNONC.A058942
P J Hoskins, K D Swenerton, Oral etoposide is active against platinum-resistant epithelial ovarian cancer. Journal of Clinical Oncology. ,vol. 12, pp. 60- 63 ,(1994) , 10.1200/JCO.1994.12.1.60
M Markman, W Hoskins, RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN CANCER: A CRITICAL NEED FOR PRECISE DEFINITIONS OF THE TREATED POPULATION Journal of Clinical Oncology. ,vol. 10, pp. 513- 514 ,(1992) , 10.1200/JCO.1992.10.4.513
Alan N. Gordon, John T. Fleagle, David Guthrie, David E. Parkin, Martin E. Gore, Angel J. Lacave, Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan Journal of Clinical Oncology. ,vol. 19, pp. 3312- 3322 ,(2001) , 10.1200/JCO.2001.19.14.3312
R. F. Ozols, Treatment goals in ovarian cancer. International Journal of Gynecological Cancer. ,vol. 15, pp. 3- 11 ,(2005) , 10.1111/J.1525-1438.2005.15351.X
MT Seymour, JL Mansi, CJ Gallagher, ME Gore, PG Harper, TRJ Evans, PM Edmonds, ML Slevin, Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease British Journal of Cancer. ,vol. 69, pp. 191- 195 ,(1994) , 10.1038/BJC.1994.33
Süleyman Alici, Pinar Saip, Yeşim Eralp, Adnan Aydiner, Erkan Topuz, Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC) American Journal of Clinical Oncology. ,vol. 26, pp. 358- 362 ,(2003) , 10.1097/01.COC.0000020590.62677.E0